seed
Stage
2021
Founded
2
Investors
About
Thymmune Therapeutics develops a machine learning-driven platform to engineer iPSC-derived thymic cells at scale, aiming to restore immune function in aging and disease by addressing thymus-related immune decline and disorders.
Explore Thymmune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.